The investigators will collect data of patients treated surgically for impending or pathological fracture of the proximal femur due to bone metastases between 01/01/2000 and 31/12/2023 with IMN or THA or HHA or MegaTHA or Mega.
After pre-screening the databases of the respective sites, the investigators expect to find approximately a total of 600 patients. A review will be made from the medical records, radiological imaging, and histological data of partecipants.
Male and female adult patients surgically treated between 01/01/2000 and 31/12/2023 in Rizzoli Orthopaedic Institute and in Massachusetts General Hospital.
Age ≥18 y (at the time of surgery)
Patients with impending or pathological fracture due to bone metastases of the proximal femur (head/neck, intertrochanteric, subtrochanteric area).
Patients who underwent either IMN or THA or HHA or Mega or MegaTHA.
Patients with pathological or impending fracture of proximal femur due to primary bone tumor.
Male and female adult patients surgically treated between 01/01/2000 and 31/12/2023 in Rizzoli Orthopaedic Institute and in Massachusetts General Hospital.
Cohort
Retrospective
Analysis
Other interventionAnalysis and review of imaging and clinical data
Analysis of implant survival
Assess the longevity associated with the different surgical treatments used for proximal femur bone metastases.
Analysis of complications
Assess the post-operative complications associated with the different surgical treatments used for proximal femur bone metastases.
Analysis of functional score
Assess the functional score associated with the different surgical treatments used for proximal femur bone metastases.
Click on the lead sponsor to view all of their trials.
Costantino Errani
Lead sponsor
Istituto Ortopedico Rizzoli
Sponsor institution
